Formulation
Formulation and Analytics Platforms Transforming Drug Product Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-25-NI-06Jul 16, 2025
Platforms
Built for Speed and Scale: How CDMO Cell Line Platforms Are Reshaping Biologic Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-25-NI-05Jul 15, 2025
Biomanufacturing
What are the most significant manufacturing hurdles in biopharma and how can they be addressed?
Pharma's Almanac
PAO-06-25-RT-02Jun 30, 2025
Health Equity
How is the pharmaceutical industry addressing global health inequities?
Pharma's Almanac
PAO-05-25-RT-01Jun 17, 2025
Next-Gen Biologics
What do you see as the next big modality in biologics, and what factors are driving innovation in this space?
Pharma's Almanac
PAO-04-25-RT-01May 01, 2025
Commitment to ESG Principles
How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?
Pharma's Almanac
PAO-03-24-CL-03Mar 08, 2024
Accelerating Product Development
What strategies are being employed to accelerate product development and commercialization without compromising quality?
Pharma's Almanac
PAO-03-24-CL-02Mar 08, 2024
Unmet Needs
In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?
Pharma's Almanac
PAO-06-022--RT-01Jun 24, 2022
Industry Challenges
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
Pharma's Almanac
O-06-022--RT-01Jun 24, 2022
Leadership
Q: What’s the key to being a leader in the industry?
Pharma's Almanac
PAO-03-022-RT-02Mar 11, 2022
Milestones
Q: What important company milestone do you anticipate reaching in 2022?
Pharma's Almanac
PAO-03-022-RT-01Mar 11, 2022
Facility
WuXi Biologics Completes Weather-Tight Seal of its Biologics Manufacturing Facility in Ireland
WuXi Biologics
PR-M03-20-NI-019Mar 12, 2020
Coronavirus
WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19
WuXi Biologics
PR-M02-20-NI-033Feb 25, 2020
Clinical Results
WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321
WuXi Biologics
PR-M02-20-NI-032Feb 24, 2020
Coronavirus
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus
WuXi Biologics
PR-M01-20-NI-041Jan 29, 2020
M&A
Wuxi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany
WuXi Biologics
PR-M01-20-NI-025Jan 16, 2020
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
WuXi Biologics
PA1806Jan 09, 2020
Drug Development
WuXi Biologics Congratulates Tychan on the World’s First Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers
WuXi Biologics
PR-M11-19-NI-018Nov 19, 2019
Expansion
WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing
WuXi Biologics
PR-M06-19-NI-054Jun 27, 2019
Vaccine
WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract
WuXi Biologics
PR-M05-19-NI-070May 24, 2019